TSW
NNVC icon

Thompson Siegel & Walmsley’s NanoViricides NNVC Stock Holding History

Thompson Siegel & Walmsley’s Portfolio NNVC Stock Details NNVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-36
Closed -$1K – 923
2016
Q4 		$1K Buy
+36
New +$960 ﹤0.01% 831

Other funds holding NNVC

Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Thompson Siegel & Walmsley's NNVC Position: Q1 2017 in Review

Thompson Siegel & Walmsley sold out of NanoViricides (NNVC) in Q1 2017, closing a stake of 36 shares — an estimated $1K sold.

Thompson Siegel & Walmsley first reported a position in NNVC in Q4 2016 and held it in 1 quarter. The position peaked at $1K in Q4 2016. 39 funds tracked by Wall St. Rank hold NNVC as of Q1 2017.

  • Thompson Siegel & Walmsley reported no remaining NanoViricides position as of Q1 2017 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 36 NanoViricides shares in Q1 2017, an estimated $1K.
  • Thompson Siegel & Walmsley first reported a position in NanoViricides in Q4 2016 and held it in 1 quarter.
  • Thompson Siegel & Walmsley's NanoViricides position peaked at $1K in Q4 2016.
  • 39 funds tracked by Wall St. Rank held NanoViricides as of Q1 2017.

Based on Thompson Siegel & Walmsley's 13F filing for Q1 2017, filed 15 May 2017.